On May 28, the official website of the Hong Kong Stock Exchange (HKEX) showed that Lupeng Pharmaceutical filed an IPO application.Lupeng Pharmaceutical was established in 2015, focusing on oncology and autoimmune diseases.Co-founder, Chief Executive Officer (CEO) and Chief Medical Officer (CMO) isDr. Fenlai Tan,Co-Founder, Executive Director, Chief Scientific Officer (CSO)forDr. Chen Yi.To date, Lupeng Pharmaceutical has completed multiple financing rounds (Seed, Series A, Series A+, Pre-Series B Phase I, Pre-Series B Phase II, and Series B), raising a cumulative total of approximately USD 213.2 million (converted at this year's average exchange rate of 1 USD = 6.93 RMB, equivalent to approximately RMB 1.477 billion). The post-money valuation following the previous round was approximately USD 311.25 million (equivalent to approximately RMB 2.157 billion).Since its establishment, Lupeng Pharmaceutical has developed the BeyondX oral medicinal chemistry platform, advancing six pipeline projects, with its core product being the BTK inhibitor lobrutinib (LP-168).Lobrutinib is a fourth-generation BTK inhibitor featuring a "covalent + noncovalent" dual-binding mechanism. The drug has a half-life of approximately 17 hours, high oral bioavailability, and excellent selectivity, and holds promise for overcoming resistance to the first three generations of BTK inhibitors.In clinical studies, lofatinib demonstrated excellent safety, with a discontinuation rate due to treatment-related adverse events (TRAEs) of only 0.7%, significantly lower than that of ibrutinib (~26%), acalabrutinib (13%–22%), zanubrutinib (2%–13%), and pirtobrutinib (9%).In August 2024, Hansoh Pharma and Lupeng Pharmaceutical entered into a cooperation agreement, obtainingLobutinibThe rights to the research and development, registration, manufacturing, and commercialization of all non-oncology indications in China (including Hong Kong, Macao, and Taiwan), with a total transaction value exceeding RMB 700 million.Based on Phase II clinical data, lobrectinib filed a marketing authorization application in May 2025 and is expected to receive conditional approval from the National Medical Products Administration (NMPA) in June 2026, poised to become China's first approved fourth-generation BTK inhibitor.Additionally, Lupeng Pharmaceutical initiated two head-to-head Phase III clinical trials in January 2026, comparing zanubrutinib, orelabrutinib, acalabrutinib, ibrutinib, and pirtobrutinib.According to the prospectus, Lupeng Pharmaceutical reported a net loss of RMB 207 million in 2025, with net liabilities of RMB 1.068 billion and cash reserves of approximately RMB 682 million as of the end of 2025, and will rely on IPO proceeds to advance the commercialization of its core pipeline.Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and shall not be directly used as a basis for decision-making. PharmaCube assumes no liability for any losses incurred by any party arising from the use of this content.
